Jazz Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 78 to 81.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Jazz Pharmaceuticals Stock A Buy?
Jazz Pharmaceuticals stock is working on a cup with handle with a 170.08 entry. See if it can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company reported -5% earnings growth in its most recent report. Sales gains came in at 34%.
Jazz Pharmaceuticals stock holds the No. 8 rank among its peers in the Medical-Ethical Drugs industry group. Merck & Co and Bristol-Myers Squibb are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
